I think that the main DNDN news now which will boost PRR's share price will be the FDA approval annoucement for DNDN's Provenge. Everyone connected with DNDN is waiting for this news - which may come any time now up to 1st May (which of course has been set as the deadline date for approval).
With such positive results for DNDN - now updated yeaterday - and such wide public interest from both DNDN shareholders and prostate cancer patientsin need of immediate attention, the FDA are probably under a lot of pressure to approve the product ASAP.
here's hoping.
In the meantime PRR has its own news due; viz, first patient recruitment for phase 2b, Orphan Drug Status and the application for beginning of phase 3 trials in Europe.
all bodes well.
cheers
- Forums
- ASX - By Stock
- IMM
- prr share price
prr share price, page-2
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
Add IMM (ASX) to my watchlist
(20min delay)
|
|||||
Last
31.0¢ |
Change
-0.005(1.59%) |
Mkt cap ! $458.1M |
Open | High | Low | Value | Volume |
31.5¢ | 31.5¢ | 31.0¢ | $9.507K | 30.18K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
27 | 173334 | 31.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
31.5¢ | 49352 | 18 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
8 | 97636 | 0.310 |
10 | 148935 | 0.305 |
16 | 370419 | 0.300 |
5 | 71833 | 0.295 |
9 | 233134 | 0.290 |
Price($) | Vol. | No. |
---|---|---|
0.320 | 107754 | 2 |
0.325 | 336000 | 3 |
0.330 | 167871 | 3 |
0.335 | 196676 | 5 |
0.340 | 529176 | 4 |
Last trade - 10.17am 07/10/2024 (20 minute delay) ? |
Featured News
LU7
Discover the strong preliminary feasibility of the Bécancour Lithium Refinery, showcasing resilience in a low pricing environment and a strategic plan to capitalize on future price recoveries
IMM (ASX) Chart |